Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 10/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP4Z1 | Q86W10 | 5/20 | 1.00 |
| ▸ | CYP4F11 | Q9HBI6 | 2/20 | 1.00 |
| ▸ | CYP4F12 | Q9HCS2 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269299 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL4269302 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL16079472 | 0.78 | CYP3A4 (0.64) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL11420876 | 0.71 | CYP2C9 (0.58) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL1019112 | 0.71 | CYP3A4 (0.55) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL6896659 | 0.71 | CYP3A4 (0.55) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL5720593 | 0.71 | CYP3A4 (0.55) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL5720594 | 0.71 | CYP3A4 (0.55) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL5838115 | 0.69 | SKP2 (0.68) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL2475751 | 0.69 | NPC1 (0.62) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120189534-A | Research method for influence mechanism of HET0016 on blood brain barrier injury | 重庆医科大学附属第二医院 | 2025-06-24 | — | — | CN | claimed |
| CN-118161472-A | Application of lauric acid inhibitor in preparation of medicines for preventing bacterial meningitis | 吉林大学 | 2024-06-11 | — | — | CN | claimed |
| CN-116676386-A | Application of CYP4F2 and CYP4F11 as ER+ breast cancer diagnosis and treatment targets | 南开大学 | 2023-09-01 | — | — | CN | claimed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-12479821-B2 | Quinoline compound and use thereof | MBD Co., Ltd. (KR) | 2025-11-25 | — | — | US | disclosed |
| CN-120189534-A | Research method for influence mechanism of HET0016 on blood brain barrier injury | 重庆医科大学附属第二医院 | 2025-06-24 | — | — | CN | disclosed |
| CN-120189534-A | Research method for influence mechanism of HET0016 on blood brain barrier injury | 重庆医科大学附属第二医院 | 2025-06-24 | — | — | CN | disclosed |
| CN-120189534-A | Research method for influence mechanism of HET0016 on blood brain barrier injury | 重庆医科大学附属第二医院 | 2025-06-24 | — | — | CN | disclosed |
| EP-4506344-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | Bebetter Med Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | BEBETTER MED INC. (CN) | 2025-01-30 | — | — | US | disclosed |
| CN-116676386-A | Application of CYP4F2 and CYP4F11 as ER+ breast cancer diagnosis and treatment targets | 南开大学 | 2023-09-01 | — | — | CN | disclosed |
| CN-116249787-A | Treatment of obesity with inhibitors of G protein-coupled receptor 75 (GPR 75) | 雷杰纳荣制药公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4168548-A1 | TREATMENT OF OBESITY WITH G-PROTEIN COUPLED RECEPTOR 75 (GPR75) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220411870-A1 | Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | MBD CO., LTD (KR) | 2022-12-22 | — | — | US | disclosed |
| WO-2022235091-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | 엠비디 주식회사 | 2022-11-10 | — | — | WO | disclosed |
| US-20220218726-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | KOREA BASIC SCIENCE INSTITUTE (KR) | 2022-07-14 | — | — | US | disclosed |
| US-11359246-B2 | Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479821-B2 | Quinoline compound and use thereof | CYP4A11, CYP7A1, CYP4B1 | CYP2C9 198/4885CYP2D6 87/4885CYP3A4 9/4885 |
| US-20220218726-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | CYP4A11, CYP46A1, CYP27A1 | CYP2C9 79/4885CYP2D6 118/4885CYP3A4 40/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | CYP2C9 59/4885CYP2D6 41/4885CYP3A4 6/4885 |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | CYP4A11, CYP4B1, CYP4A22 | CYP2C9 194/4885CYP2D6 81/4885CYP3A4 8/4885 |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | CYP2C9 84/4885CYP2D6 97/4885CYP3A4 9/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | CYP2C9 84/4885CYP2D6 97/4885CYP3A4 9/4885 |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | CYP46A1, CYP4A22, CYP2C19 | CYP2C9 35/4885CYP2D6 60/4885CYP3A4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.